1887

Journal of Medical Microbiology logo

Volume 73, Issue 9

Unveiling the complexity of rifampicin drug susceptibility testing in : comparative analysis with next-generation sequencing No Access

Graphical Abstract

Graphical abstract

Abstract

The discordance between phenotypic and molecular methods of rifampicin (RIF) drug susceptibility testing (DST) in poses a significant challenge, potentially resulting in misdiagnosis and inappropriate treatment.

A comparison of RIF phenotypic and molecular methods for DST, including whole genome sequencing (WGS), may provide a better understanding of resistance mechanisms.

This study aims to compare RIF DST in using two phenotypic and molecular methods including the GeneXpert RIF Assay (GX) and WGS for better understanding.

The study evaluated two phenotypic liquid medium methods [Lowenstein-Jensen (LJ) and Mycobacterium Growth Indicator Tube (MGIT)], one targeted molecular method (GX), and one WGS method. Moreover, mutational frequency in and was also screened in the current and previous RIF resistance genomic isolates to find their compensatory role.

A total of 25 RIF-resistant isolates, including nine from treatment failures and relapse cases with both discordant and concordant DST results on LJ, MGIT and GX, were subjected to WGS. The phenotypic DST results indicated that 11 isolates (44%) were susceptible on LJ and MGIT but resistant on GX. These isolates exhibited multiple mutations in , including Thr444>Ala, Leu430>Pro, Leu430>Arg, Asp435>Gly, His445>Asn and Asn438>Lys. Conversely, four isolates that were susceptible on GX and MGIT but resistant on LJ were wild type for in WGS. However, these isolates possessed several novel mutations in the PonA1 gene, including a 10 nt insertion and two nonsynonymous mutations (Ala394>Ser, Pro631>Ser), as well as one nonsynonymous mutation (Pro780>Arg) in PonA2. The discordance rate of RIF DST is higher on MGIT than on LJ and GX when compared to WGS. These discordances in the Delhi/CAS lineages were primarily associated with failure and relapse cases.

The WGS of RIF resistance is relatively expensive, but it may be considered for isolates with discordant DST results on MGIT, LJ and GX to ensure accurate diagnosis and appropriate treatment options.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): discordance , drug susceptibility testing , Mycobacterium tuberculosis and whole genome sequencing
© 2024 The Authors
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001884
2024-09-04
2024-10-06
Loading full text...

Full text loading...

References

  1. Harding E. WHO global progress report on tuberculosis elimination. Lancet Respirat Med 2020; 8:19 [View Article]
     [Google Scholar]
  2. Law S, Piatek AS, Vincent C, Oxlade O, Menzies D. Emergence of drug resistance in patients with tuberculosis cared for by the Indian health-care system: a dynamic modelling study. Lancet Public Health 2017; 2:e47–e55 [View Article] [PubMed]
     [Google Scholar]
  3. The Lancet Microbe Drug-resistant tuberculosis: the next sequence of events. Lancet Microbe 2024; 5:e1 [View Article] [PubMed]
     [Google Scholar]
  4. Mahomed S, Mlisana K, Cele L, Naidoo K. Discordant line probe genotypic testing vs culture-based drug susceptibility phenotypic testing in TB endemic KwaZulu-Natal: impact on bedside clinical decision making. J Clin Tuberc Other Mycobact Dis 2020; 20:100176 [View Article] [PubMed]
     [Google Scholar]
  5. Dutta NK, Mehra S, Didier PJ, Roy CJ, Doyle LA et al. Genetic requirements for the survival of tubercle bacilli in primates. J Infect Dis 2010; 201:1743–1752 [View Article] [PubMed]
     [Google Scholar]
  6. Meeting report of the WHO expert consultation on drug-resistant tuberculosis treatment outcome definitions; 2020 https://www.who.int/publications-detail-redirect/9789240022195 accessed 27 May 2023
  7. Prasad R, Gupta N, Banka A. Multidrug-resistant tuberculosis/rifampicin-resistant tuberculosis: principles of management. Lung India 2018; 35:78–81 [View Article] [PubMed]
     [Google Scholar]
  8. WHO WHO Global Tuberculosis Report 2019. WHO; 2019 http://www.who.int/tb/publications/global_report/en/
  9. Farhat MR, Sixsmith J, Calderon R, Hicks ND, Fortune SM et al. Rifampicin and rifabutin resistance in 1003 Mycobacterium tuberculosis clinical isolates. J Antimicrob Chemother 2019; 74:1477–1483 [View Article] [PubMed]
     [Google Scholar]
  10. Khan AS, Phelan JE, Khan MT, Ali S, Qasim M et al. Characterization of rifampicin-resistant Mycobacterium tuberculosis in Khyber Pakhtunkhwa, Pakistan. Sci Rep 2021; 11:14194 [View Article] [PubMed]
     [Google Scholar]
  11. Amusengeri A, Khan A, Tastan Bishop Ö. The structural basis of Mycobacterium tuberculosis RpoB drug-resistant clinical mutations on rifampicin drug binding. Molecules 2022; 27:885 [View Article] [PubMed]
     [Google Scholar]
  12. Ullah I, Shah AA, Basit A, Ali M, Khan A et al. Rifampicin resistance mutations in the 81bp RRDR of rpoB gene in Mycobacterium tuberculosis clinical isolates using Xpert MTB/RIF in Khyber Pakhtunkhwa, Pakistan: a retrospective study. BMC Infect Dis 2016; 16:413 [View Article] [PubMed]
     [Google Scholar]
  13. Rigouts L, Gumusboga M, de Rijk WB, Nduwamahoro E, Uwizeye C et al. Rifampin resistance missed in automated liquid culture system for Mycobacterium tuberculosis isolates with specific rpoB mutations. J Clin Microbiol 2013; 51:2641–2645 [View Article] [PubMed]
     [Google Scholar]
  14. W WHO announces updated definitions of extensively drug-resistant tuberculosis. n.d https://www.who.int/news/item/27-01-2021-who-announces-updated-definitions-of-extensively-drug-resistant-tuberculosis accessed 28 May 2023
  15. Conkle-Gutierrez D, Ramirez-Busby SM, Gorman BM, Elghraoui A, Hoffner S et al. Novel and reported compensatory mutations in rpoABC genes found in drug resistant tuberculosis outbreaks. Front Microbiol 2023; 14:1265390 [View Article] [PubMed]
     [Google Scholar]
  16. Miotto P, Cabibbe AM, Borroni E, Degano M, Cirillo DM. Role of disputed mutations in the rpoB gene in interpretation of automated liquid MGIT culture results for rifampin susceptibility testing of Mycobacterium tuberculosis. J Clin Microbiol 2018; 56:e01599-17 [View Article] [PubMed]
     [Google Scholar]
  17. Comas I, Borrell S, Roetzer A, Rose G, Malla B et al. Whole-genome sequencing of rifampicin-resistant Mycobacterium tuberculosis strains identifies compensatory mutations in RNA polymerase genes. Nat Genet 2012; 44:106–110 [View Article]
     [Google Scholar]
  18. Brandis G, Wrande M, Liljas L, Hughes D. Fitness-compensatory mutations in rifampicin-resistant RNA polymerase. Mol Microbiol 2012; 85:142–151 [View Article] [PubMed]
     [Google Scholar]
  19. Farhat MR, Shapiro BJ, Kieser KJ, Sultana R, Jacobson KR et al. Genomic analysis identifies targets of convergent positive selection in drug-resistant Mycobacterium tuberculosis. Nat Genet 2013; 45:1183–1189 [View Article] [PubMed]
     [Google Scholar]
  20. Qadir M, Faryal R, Khan MT, Khan SA, Zhang S et al. Phenotype versus genotype discordant rifampicin susceptibility testing in tuberculosis: implications for a diagnostic accuracy. Microbiol Spectr 2024; 12:e0163123 [View Article] [PubMed]
     [Google Scholar]
  21. Kang H, Sung N, Lee S, Kim D, Jeon D et al. Comparison of smear and culture positivity using NaOH method and NALC-NaOH method for sputum treatment. Tuberc Respir Dis 2008; 65:379 [View Article]
     [Google Scholar]
  22. Kubica GP, Dye WE, Cohn ML, Middlebrook G. Sputum digestion and decontamination with N-acetyl-L-cysteine-sodium hydroxide for culture of mycobacteria. Am Rev Respir Dis 1963; 87:775–779 [View Article] [PubMed]
     [Google Scholar]
  23. Siddiqi S, Ahmed A, Asif S, Behera D, Javaid M et al. Direct drug susceptibility testing of Mycobacterium tuberculosis for rapid detection of multidrug resistance using the Bactec MGIT 960 system: a multicenter study. J Clin Microbiol 2012; 50:435–440 [View Article] [PubMed]
     [Google Scholar]
  24. Canetti G, Fox W, Khomenko A, Mahler HT, Menon NK et al. Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes. Bull World Health Organ 1969; 41:21–43 [PubMed]
     [Google Scholar]
  25. Van Deun A, Wright A, Zignol M, Weyer K, Rieder HL. Drug susceptibility testing proficiency in the network of supranational tuberculosis reference laboratories. Int J Tuberc Lung Dis 2011; 15:116–124 [PubMed]
     [Google Scholar]
  26. Minas K, McEwan NR, Newbold CJ, Scott KP. Optimization of a high-throughput CTAB-based protocol for the extraction of qPCR-grade DNA from rumen fluid, plant and bacterial pure cultures. FEMS Microbiol Lett 2011; 325:162–169 [View Article] [PubMed]
     [Google Scholar]
  27. Kohl TA, Utpatel C, Schleusener V, De Filippo MR, Beckert P et al. MTBseq: a comprehensive pipeline for whole genome sequence analysis of Mycobacterium tuberculosis complex isolates. PeerJ 2018; 6:e5895 [View Article] [PubMed]
     [Google Scholar]
  28. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K et al. The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 2010; 20:1297–1303 [View Article] [PubMed]
     [Google Scholar]
  29. Allix-Béguec C, Arandjelovic I, Bi L, Beckert P, Bonnet M et al. Prediction of Susceptibility to First-Line Tuberculosis Drugs by DNA Sequencing. N Engl J Med 2018; 379:1403–1415 [View Article] [PubMed]
     [Google Scholar]
  30. Dheda K, Gumbo T, Maartens G, Dooley KE, McNerney R et al. The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. Lancet Respir Med 2017; 5:291–360 [View Article] [PubMed]
     [Google Scholar]
  31. Li M, Lu J, Lu Y, Xiao T, Liu H et al. rpoB mutations and effects on Rifampin resistance in Mycobacterium tuberculosis. Infect Drug Resist 2021; 14:4119–4128 [View Article] [PubMed]
     [Google Scholar]
  32. Shea J, Halse TA, Kohlerschmidt D, Lapierre P, Modestil HA et al. Low-level rifampin resistance andrpoB mutations in Mycobacterium tuberculosis: an analysis of whole-genome sequencing and drug susceptibility test data in New York. J Clin Microbiol 2021; 59: [View Article]
     [Google Scholar]
  33. Gagneux S. Fitness cost of drug resistance in Mycobacterium tuberculosis. Clin Microbiol Infect 2009; 15:66–68 [View Article] [PubMed]
     [Google Scholar]
  34. Rifat D, Campodónico VL, Tao J, Miller JA, Alp A et al. In vitro and in vivo fitness costs associated with Mycobacterium tuberculosis RpoB mutation H526D. Future Microbiol 2017; 12:753–765 [View Article] [PubMed]
     [Google Scholar]
  35. Walker TM, Miotto P, Köser CU, Fowler PW, Knaggs J et al. The 2021 WHO catalogue of Mycobacterium tuberculosis complex mutations associated with drug resistance: a genotypic analysis. Lancet Microbe 2022; 3:e265–e273 [View Article] [PubMed]
     [Google Scholar]
  36. Campbell PJ, Morlock GP, Sikes RD, Dalton TL, Metchock B et al. Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2011; 55:2032–2041 [View Article] [PubMed]
     [Google Scholar]
  37. Park M, Lalvani A, Satta G, Kon OM. Evaluating the clinical impact of routine whole genome sequencing in tuberculosis treatment decisions and the issue of isoniazid mono-resistance. BMC Infect Dis 2022; 22:349 [View Article] [PubMed]
     [Google Scholar]
  38. Amarasinghe SL, Su S, Dong X, Zappia L, Ritchie ME et al. Opportunities and challenges in long-read sequencing data analysis. Genome Biol 2020; 21:30 [View Article] [PubMed]
     [Google Scholar]
/content/journal/jmm/10.1099/jmm.0.001884
Loading
Unveiling the complexity of rifampicin drug susceptibility testing in Mycobacterium tuberculosis: comparative analysis with next-generation sequencing
J. Med. Microbiol. 73, 001884 (2024); https://doi.org/10.1099/jmm.0.001884
/content/journal/jmm/10.1099/jmm.0.001884
/content/journal/jmm/10.1099/jmm.0.001884
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error